J Biol Chem, Vol. 274, Issue 40, 28225-28232, October 1, 1999
Inhibition of Tissue Factor-Factor VIIa-catalyzed Factor X
Activation by Factor Xa-Tissue Factor Pathway Inhibitor
A ROTATING DISC STUDY ON THE EFFECT OF PHOSPHOLIPID MEMBRANE
COMPOSITION*
Irene
Salemink
,
Jo
Franssen
,
George M.
Willems§,
H. Coenraad
Hemker
, and
Theo
Lindhout
¶
From the
Department of Biochemistry and
§ Cardiovascular Research Institute Maastricht, Maastricht
University, 6200 MD Maastricht, The Netherlands
 |
ABSTRACT |
The physiological inhibitor of tissue factor
(TF)·factor VIIa (FVIIa), full-length tissue factor pathway inhibitor
(TFPIFL) in complex with factor Xa (FXa), has a high
affinity for anionic phospholipid membranes. The role of anionic
phospholipids in the inhibition of TF·FVIIa-catalyzed FX activation
was investigated. FXa generation at a rotating disc coated with TF
embedded in a membrane composed of pure phosphatidylcholine (TF·PC)
or 25% phosphatidylserine and 75% phosphatidylcholine (TF·PSPC) was
measured in the presence of preformed complexes of
FXa·TFPIFL or FXa·TFPI1-161 (TFPI lacking
the third Kunitz domain and C terminus). At TF·PC,
FXa·TFPIFL and FXa·TFPI1-161 showed
similar rate constants of inhibition (0.07 × 108
M
1 s
1 and 0.1 × 108 M
1 s
1,
respectively). With phosphatidylserine present, the rate constant of
inhibition for FXa·TFPIFL increased 3-fold compared with
a 9-fold increase in the rate constant for
FXa·TFPI1-161. Incubation of TF·PSPC with
FXa·TFPIFL in the absence of FVIIa followed by depletion
of solution FXa·TFPIFL showed that
FXa·TFPIFL remained bound at the membrane and pursued its
inhibitory activity. This was not observed with
FXa·TFPI1-161 or at TF·PC membranes. These data
suggest that the membrane-bound pool of FXa·TFPIFL may be
of physiological importance in an on-site regulation of TF·FVIIa activity.
 |
INTRODUCTION |
Blood coagulation in vivo is initiated when circulating
factor VII(a) binds in a calcium-dependent way to its
cofactor, tissue factor (TF)1
(see Refs. 1 and 2 for a review). This complex formation results in
enhanced catalytic activity of factor VIIa (FVIIa), which via limited
proteolysis, activates factors X (FX) and IX (FIX) (3). TF is a
transmembrane glycoprotein, which under normal conditions is expressed
only in extravascular tissues (4, 5).
The main physiological regulator of TF-induced blood coagulation is
tissue factor pathway inhibitor (TFPI) (6, 7), a single chain
glycoprotein of 42 kDa and a member of the Kunitz family of serine
protease inhibitors. TFPI contains an acidic N terminus, followed by
three tandemly repeated Kunitz-type inhibition domains, and a basic
C-terminal tail (8). Site-directed mutagenesis has revealed that the
first Kunitz domain binds to FVIIa and that the second Kunitz domain
interacts with the active site of FXa (9). No such functions could be
attributed to the third Kunitz domain (10). Yet, various interactions
have been ascribed to this domain, e.g. with lipoproteins
and heparin, but their importance for the inhibitory function of TFPI
is not clear (11, 12). On the other hand, the basic C-terminal region
of TFPI (residues 240-276) has been shown to play a crucial role in
the anticoagulant activity of this inhibitor (13, 14). Despite numerous
studies, it remains unclear how this basic C terminus modulates the
anticoagulant activity of TFPI (15-19).
TFPI inhibits the generation of FXa and FIXa by the TF·FVIIa complex
in a unique, two-step reaction (20). First, TFPI binds Ca2+
independently to FXa, thereby inhibiting the FXa catalytic activity (9). In a second step, the FXa·TFPI complex binds in a
Ca2+-dependent way to TF·FVIIa. This results
in the formation of the quaternary complex
TF·FVIIa·FXa·TFPI, in which the proteolytic activity of the
TF·FVIIa complex is fully neutralized. The effect of TFPI on
TF·FVIIa activity in the absence of FXa is negligible (21, 22),
implying that the true inhibitor of TF·FVIIa activity is the
FXa·TFPI complex. The rate of complex formation of FXa and TFPI is
enhanced by negatively charged phospholipids for full-length TFPI
(TFPIFL) but not for TFPI1-161, a truncated
variant lacking the third Kunitz domain and the potential phospholipid binding C-terminal tail (16, 23).
Recently (24), we demonstrated that TFPIFL in complex with
FXa has a much higher affinity for anionic phospholipid membranes compared with that of either protein alone. It is well recognized that
the binding of blood coagulation enzymes as well as their cofactors and
substrates to membranes containing anionic phospholipids may result in
an immense increase of the catalytic efficiency of these enzymes. On
the other hand, excess binding sites could cause a lowering of both
solution concentration and surface density of the reactants (25, 26),
resulting in a decrease of reaction rates. Previous studies (17, 22,
23) did not reveal a stimulatory or interfering effect of anionic
phospholipids on the complex formation between FXa·TFPI and
TF·FVIIa. These studies, however, were performed in the presence of
excess phospholipid vesicles. It remains unclear what the role is of
lipid-protein interactions and of the TFPI C terminus when TF is
embedded in a macroscopic phospholipid membrane. Answering these
questions could provide insight in the role of (TF-bearing) cell
membranes in the regulation of the TF·FVIIa-catalyzed initiation of
the blood coagulation process.
To mimic the processes occurring at TF-bearing cell surfaces as closely
as possible, we made use of TF embedded in a macroscopic phospholipid
surface to which the reactants were supplied under well defined flow
conditions. This approach allows a quantitative study of the kinetics
of inhibition of TF·FVIIa-catalyzed FX activation as a function of
the phospholipid composition of the membrane and the
phospholipid-binding properties of the FXa·TFPI complex. Our study
showed that negatively charged phospholipid surfaces act as a safety
net in the sense that FXa·TFPIFL complexes readily bind
to the surface. These phospholipid-bound FXa·TFPIFL
complexes then show a potent inhibitory activity against TF·FVIIa
present at the same membrane.
 |
EXPERIMENTAL PROCEDURES |
Materials
Bovine serum albumin (BSA, essentially fatty acid-free) was
obtained from Sigma. The chromogenic substrate for FXa, S2765, was
purchased from Chromogenix (Mölndal, Sweden).
1,2-Dioleoyl-sn-glycero-3-phosphocholine (PC) and
1,2-dioleoyl-sn-glycero-3-phosphoserine (PS) were obtained from Avanti Polar Lipids (Alabaster, AL). All other reagents used were
of analytical grade.
Proteins
Human FX was purified according to Mertens et al.
(27). Human FXa was prepared by activation of purified FX with the FX activating protein from Russell's viper venom (Sigma) and isolated as
was described for bovine FXa (28). The molar concentration was
determined by active site titration with p-nitrophenyl
p-guanidinobenzoate hydrochloride (29). Recombinant human
TFPIFL, produced in Escherichia coli (30), was
kindly supplied by Searle/Chiron (Emeryville, CA). This recombinant
TFPIFL preparation, not being glycosylated, is very similar
to the native highly glycosylated protein expressed in mammalian cells
with respect to anticoagulant activity (16, 30). The C-terminal
truncated TFPI preparation was kindly supplied by Dr. O. Nordfang (Novo
Nordisk, Bagsvaerd, Denmark). TFPI1-161 was expressed in
Saccharomyces cerevisiae and purified as described previously (31). The molar concentrations of the TFPI preparations were
determined by titration with known amounts of FXa (18). Recombinant
human TF was a kind gift of Dr. Y. Nemerson (Mount Sinai School of
Medicine, New York, NY). Recombinant FVIIa was a kind gift of Dr. U. Hedner (Novo Nordisk).
Relipidation of Recombinant Human TF
Recombinant human TF, 20 and 100 nM, was
reconstituted with 2 mM PSPC (25 mol% PS/75 mol% PC) and
2 mM PC (100 mol% PC), respectively, using
n-octyl-
-D-glucopyranoside (Calbiochem, La
Jolla, CA) solubilization and dialysis as described (32). Because the
TF is randomly oriented in the reconstituted vesicles, we considered
the effective TF concentration to be 50% of the total concentration
present in the reconstituted preparation (32). Calculations were
therefore based on a TF:phospholipid ratio of 1:20 × 104 and 1:4 × 104 for PSPC and PC, respectively.
The Rotating Disc Device
The set-up used in the present study is a modification of the
one described previously (33). In short, a cylinder (height 12 mm,
width 16 mm) made of polyethylene terephthalate (PETP; AKZO Plastics,
Amersloont, The Netherlands), containing four tiny magnets, was
mounted on a motor with servo-controlled rotation speed. A cylindrical
vessel is placed on top of the motor-containing holder, such that the
cylinder rotates close to the glass bottom of the vessel. A glass
coverslip (Menzel Gläser, Braunschweig, Germany) with a diameter
of 20 mm is attached to another PETP cylinder (height 2 mm, width 12 mm), also containing four magnets. This second cylinder fits into a
thin PETP ring, mounted in the vessel, which guides the movements of
the rotating disc. A stationary baffle was immersed in the solution (3 ml) during the experiments to establish a well defined flow pattern.
Preparation of Phospholipid-coated Discs
The glass coverslips of the rotating discs were made hydrophilic
as described previously (34). In order to apply a TF-containing lipid
bilayer, the rotating discs (63 rad/s) were exposed for 30 min to
reconstituted vesicles in Tris buffer (50 mM Tris-HCl, pH
7.9, and 175 mM NaCl), with a final
phospholipid-concentration of 20 µM. Fluid phase vesicles
were removed by flushing for 5 min with TBSA-CaCl2 buffer
(Tris buffer containing 3 mM CaCl2 and 1 mg/ml
BSA) at a rate of 10 ml/min using a Minipuls II pump (Gilson,
Villiers-le-Bel, France). Finally the disc was transported, without
exposing the lipid surface to an air-buffer interface, to a second
vessel that had been pretreated for 1 h with 20 mg/ml BSA in Tris
buffer. Before placing the coated disc in this second vessel, the high
content BSA Tris buffer was replaced by TBSA-CaCl2 buffer.
All preparations were performed at 37 °C. The effective TF surface
density was 2.5 fmol/cm2 and 12.5 fmol/cm2 for
PSPC and PC, respectively, as calculated on the basis of a phospholipid
surface density of 0.5 nmol/cm2 and TF:phospholipid ratios
of 1:20 × 104 or 1:4 × 104. The
disc surface area was 3.14 cm2; the theoretical amount of
TF available at the surface is therefore 7.8 and 39 fmol for PSPC and
PC, respectively. Throughout this paper, TF·PSPC and TF·PC refer to
the planar surfaces thus obtained.
Measurement of FX Activation
Discs coated with TF·PSPC or TF·PC were spun at 63 rad/s in
3 ml TBSA-CaCl2 buffer. FVIIa (1 nM) was added
and incubated with the spinning disc for 5 min. The TF·FVIIa activity
was then assessed from FXa generation following the addition of FX (100 nM). Timed samples were taken from the reaction mixture and
collected into polystyrene cuvettes containing 50 mM
Tris-HCl, pH 7.9, 175 mM NaCl, 20 mM EDTA, and
0.5 mg/ml BSA, (total volume 450 µl). To determine the amount of FXa
present, 50 µl of 3 mM chromogenic substrate S2765 was
added to the cuvette, and the conversion of the chromogenic substrate
was followed at 37 °C on a dual wavelength spectrophotometer at 405 nm (reference wavelength 500 nm). The FXa concentrations were
calculated from standard curves obtained with known amounts of the
enzyme. The TF containing phospholipid surface of the rotating disc
could be reused after flushing with TBSA-EDTA buffer (20 mM
EDTA) for 5 min at 10 ml/min, followed by a rinse with
TBSA-CaCl2 buffer (5 min at 10 ml/min). All procedures were
performed at 37 °C and unless otherwise mentioned, at an angular
velocity of 63 rad/s.
Inhibition of TF·FVIIa Activity
All inhibition experiments were carried out with preformed
FXa·TFPI complexes. These complexes were prepared by incubating FXa
and TFPI at equimolar concentrations (50 nM) for 30 min at 37 °C in TBSA-CaCl2 buffer. This incubation time was
sufficiently long to obtain an equilibrium in complex formation (95%
of FXa in complex), as was established by measuring the free FXa
concentration with chromogenic substrate S2765. The inhibitory activity
of FXa·TFPI was assessed in two different ways. The first method was
by preincubating TF·PSPC or TF·PC with FVIIa (1 nM) for
5 min, then adding FX (100 nM) in the presence of various
concentrations of FXa·TFPI and subsequently assaying the timed
samples taken from the vessel for FXa activity. Under these conditions,
fluid phase inhibitor complex is assumed to be in equilibrium with
surface-bound FXa·TFPI. The second method was by preincubating
TF·PSPC or TF·PC for 10 min with 0.4 nM FXa·TFPI, in
the absence of FVIIa, and then depleting the solution of inhibitor
complex by flushing for various time intervals with
TBSA-CaCl2 buffer. Subsequently, FX activation was started
by adding FX (100 nM) and FVIIa (1 nM). Timed
samples were taken and assayed for FXa activity as described above.
Data Analysis
FVIIa Concentration-dependent FX Activation--
As
the catalytic efficiency of FVIIa in complex with TF is several orders
of magnitude higher than that of free FVIIa, the observed FX generation
rate, Vobs, reflects the formation of the binary
TF·FVIIa complex and is described by the formula shown in Equation 1,
|
(Eq. 1)
|
with [FVIIa] the free FVIIa concentration,
Kd the apparent dissociation constant of the
TF·FVIIa complex, and Vmax the FXa generation
rate at saturating FVIIa concentrations. As the amount of TF present in
the system is negligible compared with the concentration of added
FVIIa, [FVIIa] equals the total FVIIa concentration. The parameters
Vmax and Kd were determined
by least squares fitting of Equation 1 to the measurements of
Vobs.
Dependence of the FX Activation Rate on the FX
Concentration--
Measurements of the observed rate of FXa
generation, Vobs, were analyzed using the
Michaelis-Menten formula as shown in Equation 2,
|
(Eq. 2)
|
which relates Vobs to
Vmax the conversion rate at saturating FX
concentrations, [FX] the FX concentration, and
Km(app) the apparent Michaelis constant.
The parameters Vmax and
Km(app) were determined by least squares
fitting of Equation 2 to the measurements of
Vobs. It should be noted that the substrate
transport from the bulk solution to the disc surface depends on the
concentration gradient between bulk and the solution, immediately
adjacent to the catalytic surface. To what extent this substrate
depletion near the surface causes an underestimation of the true
Km value depends on the ratio of substrate
conversion over the transport-limited rate of substrate supply
(33).
Inhibition of TF·FVIIa-mediated FX Activation by Preformed
FXa·TFPI Complexes--
The decrease in FX activation rate reflects
the formation of quaternary TF·FVIIa·TFPI·FXa complexes and the
corresponding decline of TF·FVIIa activity, which for any fixed
concentration of inhibitor, can be described as a pseudo-first order
process (22, 23). Therefore, the time-dependent FXa
generation indicating a mono-exponential decay of TF·FVIIa activity
can be expressed as shown in Equation 3,
|
(Eq. 3)
|
with [FXa]t the observed FXa generation at time
t, V0 the rate of FXa generation in
the absence of inhibitor, k the pseudo-first order rate
constant of inhibition, and t the reaction time. In principle, the rate constants V0 and
k can be determined by a least squares fit of Equation 3 to
the FXa generation curve. This approach, however, is subject to the
drawback that, because of the rapid decline of the FXa generation rate,
the estimates of V0 and k become
increasingly correlated and inaccurate for increasing concentrations of
the inhibitory complex. To avoid this source of error, we employed the
excellent reproducibility of repeated measurements of FXa generation on
the same TF·PSPC/TF·PC disc after regeneration by an EDTA wash (see
"Results"). Each measurement of FX activation in the presence of
FXa·TFPI complex was preceded by a measurement of the corresponding
FXa generation in the absence of inhibitor complex. The rate constants
V0 and k were estimated by a
simultaneous least squares fit of Equation 3 to the experimental data,
with an individual parameter k for the uninhibited and the inhibited FX activation and a shared parameter
V0 for the initial rate of FXa generation.
 |
RESULTS |
Initial Rate of FX Activation at the Surface of a Rotating Disc
with TF Embedded in a Phospholipid Bilayer--
Typical results of FX
activation experiments using a rotating disc are shown in Fig.
1. The disc with TF embedded in a planar phospholipid bilayer composed of PSPC or PC was incubated first with
FVIIa (1 nM) during 5 min before FX (100 nM)
was added to start the reaction. Apparently, for both TF·PC and
TF·PSPC, the FXa activity increases linearly as a function of time.
However, the inset to Fig. 1 reveals that, in contrast to
the TF·PC surface, it takes for the TF·PSPC surface about 1 min
before FXa activity starts to increase linearly. This delayed rise in
solution FXa activity most likely reflects binding of FXa to the
TF·PSPC surface (35). Therefore, the initial rate of FX activation is
defined as the linear increase in solution phase FXa 1.5 min after the start of the reaction. When the rotation of the disc was stopped FXa
generation halted indicating that under the conditions of the
experiment convective transport is essential both for delivery of FX to
the catalytic surface and for the transfer of FXa from the surface to
the solution. No FXa was produced in the absence of TF or FVIIa.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 1.
FX activation by TF·phospholipid·FVIIa
immobilized at the surface of a rotating disc. The TF·PSPC ( ,
2.5 fmol of TF/cm2) or TF·PC ( , 12.5 fmol of
TF/cm2) surface was incubated with FVIIa (1 nM)
for 5 min in TBSA-CaCl2 buffer, and the reaction was
started by adding FX (100 nM). Samples were taken at the
indicated time points and assayed for FXa. At t = 10 min the rotation (63 rad/s) was stopped, whereas sampling was
continued. The initial rate (V0) of FX
activation, derived from the increase in FXa concentration measured
between 2 and 8 min, is 3.15 nM/min for TF·PSPC and 0.85 nM/min for TF·PC. Inset, FXa generation during
the initial phase of the reaction.
|
|
The mean value ± S.D. of the initial rate of FXa generation at
TF·PSPC after repeated regeneration (n = 5) of the
same disc (see "Experimental Procedures") was 2.99 ± 0.12 nM/min. For TF embedded in PC, the initial rate of FXa
generation was 0.82 ± 0.07 nM/min (mean value ± S.D., n = 5). A single TF·PSPC or TF·PC disc could
thus be regenerated and used several times, allowing repeating
experiments under different conditions with an unchanged catalytic
active surface. The inter-disc variations were larger with mean values
for the initial rate of FX activation ± S.D. of 3.24 ± 0.70 nM/min (n = 30) and 0.77 ± 0.37 nM/min (n = 30) for TF·PSPC and TF·PC,
respectively. It should be noted that the TF·PC membrane preparation
contained 5-fold more TF than the TF·PSPC membrane.
Dependence of the Rate of FX Activation on the Angular Velocity of
the Rotating Disc--
Fig. 2 shows the
relation between the angular velocity of the rotating disc and the
initial rate of FXa formation. For a rotating disc with TF·PSPC, the
initial rate of FXa formation increases when the angular velocity
increases from 0 to 60 rad/s. An additional increase of the angular
velocity does not result in a concomitant increase of the initial rate.
Thus, an angular velocity of more than 60 rad/s appears to be
sufficient to approach a kinetically controlled situation. That is, the
rate at which FX is activated at the surface is smaller than the
transport limited rate of FX delivery to the catalytic surface. A
similar experiment was also performed with TF embedded in PC (Fig. 2).
Obviously, an apparent kinetically controlled FX activation is achieved
at a lower angular velocity (30 rad/s) than observed with TF·PSPC.
The 5-fold lower rate of FX activation at the TF·PC surface likely
reduces the transport-limited supply of reactants. All further
experiments were performed at an angular velocity of 63 rad/s.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Dependence of the initial velocity of FX
activation on the angular velocity of the rotating discs. At the
indicated angular velocities, the initial rate of FX activation was
measured on TF·PSPC ( ) and TF·PC ( ) as described in the
legend to Fig. 1. A single rotating disc was used that was regenerated
for each measurement by flushing (10 ml/min) the reaction vessel and
spinning disc for 5 min with TBSA-EDTA and subsequently for 5 min with
TBSA-CaCl2 buffer.
|
|
Kinetic Parameters for FX Activation at the Rotating
Disc--
Based on a previously reported Kd value
of 41 pM for FVIIa binding to TF in PSPC vesicles (36), we
reckoned that a FVIIa concentration of 1 nM, as used in the
experiments described above, was sufficient to saturate all the TF
exposed at the catalytic surface. To verify whether this assumption
applied for the rotating disc system, we measured the initial rate of
FX activation as a function of the solution phase FVIIa concentration.
The titration curves obtained (data not shown) were analyzed using
Equation 1 to yield binding as well as kinetic parameters. For
TF·PSPC the fit yielded a Kd of 18 pM,
and for TF·PC the Kd value was 240 pM.
Thus, whereas the Kd of FVIIa for TF·PSPC is in
good agreement with the value previously reported (36, 37), the
affinity of FVIIa for TF·PC is 10-fold higher than values reported by
others (32, 36). Hence, a FVIIa concentration of 1 nM is
indeed sufficient to saturate more than 80% of the TF present at the
PC and PSPC surfaces. Furthermore, the fit yielded a
Vmax of 4.4 nM/min (TF·PSPC) and
0.85 nM/min (TF·PC), corresponding to a turnover number
of 1677/min for TF·PSPC and of 65/min for TF·PC.
Likewise, the relationship between the initial rate of FX activation at
the spinning surface and the fluid-phase FX concentration was
determined for TF·PSPC and TF·PC. By fitting Equation 2 to the
experimental data (not shown), we estimated values of 110 nM for the apparent Km
(Km(app)) and of 5.5 nM/min
for Vmax. Calculation on basis of an estimated
TF density of the PSPC surface (2.5 fmol/cm2) gave a
kcat value of 2098/min for TF·PSPC. For
TF·PC a linear relation between the FXa generation rate and the FX
concentration was found despite a much higher (up to 400 nM) FX concentration employed (data not shown). This
indicated for the TF·PC a Km(app) value of > 5 µM, thus at least 1 order of magnitude
greater than the highest FX concentration used.
Inhibition of Membrane-associated TF·FVIIa as a Function of the
Concentration of FXa·TFPI--
In a successive set of experiments,
we assessed the inhibitory activity of preformed
FXa·TFPIFL and FXa·TFPI1-161 complexes toward TF·FVIIa-catalyzed FX activation at TF·PC and TF·PSPC
membranes deposited on rotating discs. Following a preincubation with
FVIIa for 5 min, the reaction was started by the simultaneous addition of FX (100 nM) and inhibitor complexes in varying
concentrations. All inhibition experiments were preceded by a control
experiment in the absence of inhibitor to assess the precise catalytic
activity of that particular rotating disc. To correct for inter-disc
variations in catalytic activity (± 20%, as shown before), the FXa
generated in the presence of inhibitor is expressed as a percentage of
the corresponding amount of FXa generated after 10 min in the absence of inhibitor.
It is seen from Fig. 3A that
the rate of FXa generation on TF·FVIIa·PC in the presence of
FXa·TFPI1-161 gradually decreases in time and that this
progressive inhibition becomes more pronounced at higher inhibitor
concentrations. The very same observations were made with
FXa·TFPIFL as inhibitor (Fig. 3B). The FXa
generation curves were analyzed according to a model that assumes that
complex formation between TF·FVIIa and FXa·TFPI results in a
quaternary complex in which the catalytic activity of TF·FVIIa is
completely blocked (Equation 3, see "Experimental Procedures"). The
hypothesis that the initial FXa generation rate did not alter by
addition of the FXa·TFPI complex was checked by fitting Equation 3 to
the individual curves of the pairs of uninhibited and inhibited FXa generation. The value obtained for V0 of the
inhibited curve, expressed as percentage of V0
of the uninhibited curve, was 96 ± 6% and 105 ± 9%
(mean ± S.D.; n = 6) for
FXa·TFPI1-161 and FXa·TFPIFL complexes,
respectively. These data thus justify our analysis of the FXa
generation curves by a simultaneous fit of Equation 3 to the
uninhibited and inhibited curves with a shared rate constant
V0. The solid lines in
Fig. 3 (A and B) show the result of this fitting
procedure, which yielded pseudo-first order rate constants of
inhibition (k) as a function of the concentration of the
inhibitory complex (Fig. 3C). It is clear that k
increases linearly with the concentration of the inhibitory complex.
This indicates that, in the concentration range employed, the
bimolecular association of TF·FVIIa with preformed FXa·TFPI is the
rate-limiting step of the formation of the quaternary
TF·FVIIa·FXa·TFPI complex. The second order rate constants of
inhibition (Table I) as were obtained by
linear regression to these data, were similar for FXa·TFPI1-161 and FXa·TFPIFL, namely
0.10 × 108
M
1·s
1 and 0.07 × 108 M
1·s
1.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Inhibitory activity of FXa·TFPI toward
TF·FVIIa·PC. The TF·PC surface was incubated with FVIIa (1 nM) for 5 min. Subsequently the reaction was started by
adding FX (100 nM), in the absence ( ) or presence of 0.2 ( ), 0.4 ( ), or 0.8 ( ) nM
FXa·TFPI1-161 (panel A) or
FXa·TFPIFL (panel B). Samples were
taken at the indicated time points and assayed for FXa activity, which
is expressed as a percentage of the amount of FXa formed after 10 min
in the absence of inhibitor. The solid lines are
drawn according to the best fit of Equation 3 to the experimental data.
In panel C, the rate constants obtained by the
fit are plotted as a function of FXa·TFPIFL ( )
and FXa·TFPI1-161 ( ) concentration.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Second order rate constant of inhibition of TF·FVIIa as determined
from inhibition of TF·FVIIa-mediated FX activation at the
phospholipid surface of a rotating disc
|
|
The same experiments were performed with TF embedded in PSPC.
Comparison of Figs. 4A and
3A shows that FXa·TFPI1-161 inhibits
TF·FVIIa more efficiently at a PSPC surface than at a PC surface. A
solution phase concentration of 0.4 nM
FXa·TFPI1-161 is sufficient to neutralize TF·FVIIa
activity almost instantaneously. In contrast, with the same
concentration of FXa·TFPIFL complex at TF·PSPC (Fig.
4B), a significant FXa generation is still observed. The FXa
generation curves as shown in Fig. 4 were analyzed as described for
those in Fig. 3. The pseudo-first order rate constants of inhibition
thus obtained are presented in Fig. 4C as a function of the
concentration of the inhibitory complex. This plot clearly reveals the
difference in inhibitory activity of FXa·TFPI1-161 and
FXa·TFPIFL on TF·PSPC. According to Table I, the second
order rate constant of inhibition for FXa·TFPI1-161 and
FXa·TFPIFL increases when PS is present in the TF-bearing
membrane. However, the increase for FXa·TFPI1-161 is
about 9-fold, whereas a 3-fold increase is seen for
FXa·TFPIFL. The rate constant of 0.94 × 108 M
1·s
1 found
for FXa·TFPI1-161 is in good agreement with the previous reported value of 1.1 × 108
M
1·s
1 (23), whereas the value
for FXa·TFPIFL (0.20 × 108
M
1·s
1) is 5-10 fold lower
than the values reported previously (22, 23). Thus at TF·PSPC,
FXa·TFPIFL apparently has a lower inhibitory activity
than FXa·TFPI1-161. In view of our earlier finding that
FXa·TFPIFL complexes have a considerably higher affinity for PS containing lipid membranes than complexes of
FXa·TFPI1-161, these data suggest that upon binding to
TF·PSPC, FXa·TFPIFL complexes lost their inhibitory
action.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibitory activity of FXa·TFPI toward
TF·FVIIa·PSPC. The experiment was performed essentially as
described in the legend to Fig. 3 but now with a TF·PSPC surface.
Panel A, 0 ( ), 0.025 ( ), 0.05 ( ), 0.1 ( ), 0.2 ( ), or 0.4 ( ) nM
FXa·TFPI1-161. Panel B, 0 ( ),
0.1 ( ), 0.2 ( ), 0.4 ( ), or 0.8 ( ) nM
FXa·TFPIFL. The solid lines are
drawn according to the best fit of Equation 3 to the FXa generation
curves. In panel C, the rate constants thus
obtained are plotted as a function of FXa·TFPIFL ( )
and FXa·TFPI1-161 ( ) concentration.
|
|
Inhibition of TF·FVIIa-catalyzed FX Activation by Membrane-bound
FXa·TFPI Complex--
FXa·TFPIFL and
FXa· TFPI1-161 complexes (0.4 nM) were
incubated for 10 min with TF·PSPC-coated discs spinning at 63 rad/s.
In some cases FXa·TFPI complexes were, after the incubation, removed
from the solution by flushing the reaction vessel with a
TBSA-CaCl2 buffer during 5 min at 10 ml/min. FXa generation was initiated by the simultaneous addition of FX (100 nM)
and FVIIa (1 nM). Fig.
5A shows the time courses of
FXa generation for TF·PSPC surfaces that were preincubated with
FXa·TFPI1-161 with inhibitor complexes remaining in
solution during the FXa generation and with inhibitor complexes removed
from solution at the end of the preincubation. For comparison we also
show the FXa generation in the absence of inhibitory complexes and the FXa generation as observed when the inhibitory complexes were added
simultaneously with FX. It is apparent from Fig. 5A that, as
long as the FXa·TFPI161 is not depleted from the
solution, identical inhibition is seen with or without preincubation,
whereas depletion of the inhibitory complex from the solution
completely removes the inhibitory activity.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Retention of TF·PSPC membrane-bound
inhibitory activity. The TF·PSPC disc surface was preincubated
for 10 min with 0.4 nM FXa·TFPI1-161
(panel A) and 0.4 nM
FXa·TFPIFL (panel B). Then the
reaction vessel and rotating disc were either not flushed ( ) or
flushed (10 ml/min) for 5 min with TBSA-CaCl2 buffer ( ).
FX activation was started by addition of FVIIa (1 nM) and
FX (100 nM). For comparison data from Fig. 4 are shown: FX
activation in the absence of inhibitor ( ) and the inhibition of FX
generation when the inhibitory complex is added simultaneously with FX
( ). Solid lines indicate the best fit of
Equation 3 to the individual curves. The FXa activity is presented as a
percentage of the amount of FXa formed 10 min after the start of the
reaction in the absence of inhibitor.
|
|
Similar experiments performed with FXa·TFPIFL complexes
gave a completely different outcome, as shown in Fig. 5B.
The largest extent of inhibition of FXa generation is observed when the
TF·PSPC membrane was preincubated with FXa·TFPIFL
complexes. Even more strikingly, it turned out that depletion of the
solution from FXa·TFPIFL complex by flushing the reaction
vessel at the end of the preincubation did not diminish the inhibitory
activity. This indicates that under the conditions of this experiment,
the contribution of TF·PSPC-bound FXa·TFPIFL complexes
to the inhibitory activity is dominant. To ascertain that the
inhibitory activity that remained manifest after flushing originated
from FXa·TFPIFL bound to the TF·PSPC surface and not
from inhibitory complex nonspecifically bound to the wall of the
reaction vessel, we performed the following control experiment. The
reaction vessel was preincubated for 10 min with 0.4 nM
FXa·TFPIFL and flushed for 5 min with
TBSA-CaCl2 buffer, after which an unused TF·PSPC-coated
disc was placed in the vessel. Subsequently, the rate of FXa formation
at that disc was measured following the addition of FVIIa (1 nM) and FX (100 nM). No inhibition was
observed, showing that the retained inhibitory activity in the previous
experiment solely originated from TF·PSPC-bound FXa·TFPIFL complexes.
The different effects of flushing on the inhibitory activity (Fig. 5,
A and B) of the FXa·TFPI1-161 and
FXa·TFPIFL complexes at TF·PSPC presumably reflect the
differences in desorption rates of these complexes that were previously
reported (24). As has been shown, at a macroscopic PSPC surface (no TF
present) the residence time of membrane-bound FXa·TFPIFL
was about 45 min, compared with a residence time of about 1-2 min for
complexes of FXa with TFPI1-161. When a TF·PC surface
was preincubated with FXa·TFPIFL (0.4 nM) and
subsequently washed for 5 min as described above, an uninhibited FXa
generation was observed (data not shown). Thus, omitting the negatively
charged phospholipids from the membrane resulted in loss of
FXa·TFPIFL membrane binding and thus of the exerted
inhibitory activity. Additional support was obtained when, following
the preincubation of the TF·PSPC surface with
FXa·TFPIFL, the time period of flushing with buffer was
increased (from 5 to 90 min). This resulted in a gradually decreasing
inhibitory activity (Fig. 6). It is
noteworthy, however, that even after a rinse for 90 min, a significant
inhibition of FXa generation is still observed.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 6.
Time-dependent decrease of the
inhibitory activity of FXa·TFPIFL complexes preadsorbed
on TF·PSPC. The TF·PSPC disc surface was preincubated for 10 min with FXa·TFPIFL (0.4 nM). Then the
reaction vessel and rotating disc were flushed for 5 ( ), 45 ( ),
or 90 ( ) min with TBSA-CaCl2 buffer (10 ml/min). FX
activation was started by addition of FVIIa (1 nM) and FX
(100 nM). FXa generation in the absence of inhibitor is
indicated by the closed circles. Solid lines indicate the best fit of Equation 3 to the individual
curves. The FXa activity is presented as a percentage of the amount of
FXa formed after 10 min in the absence of inhibitor.
|
|
Further analysis of inhibited and uninhibited FXa generation curves, as
presented in Figs. 5B and 6, reveals that preincubation of
TF-PSPC with FXa·TFPIFL results in a major decrease of
the initial rate of FX activation. Correspondingly, the simultaneous fit of Equation 3 to the inhibited and the matching uninhibited FXa
generation curves with a shared rate constant
V0, as used in the fits of Figs. 3 and 4,
resulted in an inadequate fit with large systematic deviations. Using
individualized parameter values of V0, however,
resulted in excellent fits (solid lines in Figs. 5B and 6). The estimated parameters
V0 and k, listed in Table II, show that the initial rate of FXa
generation of the preincubated curves is instantaneously decreased to
about 25% of the uninhibited V0 when FXa
generation is initiated shortly (0-5 min) after the preincubation.
With increasing flushing time, a gradual increase of the estimated
V0 is observed, from 27% after 5 min flushing to 59% after 90 min of flushing. The rate constants found for the
exponential decay of the TF·FVIIa activity ranged from 0.08 to 0.15 min
1, dependent on the flushing time. These values are
3-5-fold lower than the decay rate of 0.42 min
1, found
for the inhibition of TF·FVIIa when the same concentration of
FXa·TFPIFL was added to the reaction mixture (Fig.
4).
View this table:
[in this window]
[in a new window]
|
Table II
Inhibition by membrane bound Fxa·TFPIFL
Fit parameters k and V0, see Equation 3,
as determined from TF·FVIIa-mediated FX activation initiated by
simultaneous addition of FVIIa and FX, after preincubation of the
TF:PSPC surface during 10 min with FXa·TFPIFL complexes (0.4 nM) followed by no flushing or a flush of the reaction
vessel with Ca2+-containing buffer (10 ml/min) during the
indicated period. V0 is presented as percentage of
the initial rate of FXa generation of the paired uninhibited curve
obtained at the same disc.
|
|
 |
DISCUSSION |
Rationale behind Experimental Design--
In this study we
addressed the question of whether the previously reported (24) high
affinity of FXa·TFPIFL for negatively charged
phospholipids is reflected in its inhibitory activity against
TF·FVIIa. Because phospholipids were also shown to enhance complex
formation between FXa and TFPI (16, 23), preformed FXa·TFPIFL and FXa·TFPI1-161 complexes
were used in this study to simplify the interpretation of the
experimental data on the effect of phospholipids on the TF·FVIIa
inhibition by FXa·TFPI. Furthermore, a macroscopic phospholipid
membrane (with embedded TF) was used rather than unilamellar vesicles
because this model mimics the plasma membrane of TF-bearing cells
better than small unilamellar vesicles. Moreover, several studies have
shown that the kinetics of activation and inactivation of blood
coagulation enzyme complexes are dependent on the characteristics of
the phospholipid surface like the radius of the phospholipid vesicle
(35, 38), microscopic homogeneity (39), and ratio of reactant-bearing vesicles over non-bearing vesicles (25). Additionally, with macroscopic
surfaces it is easier to separate physically the surface-bound and
fluid-phase reactions. The use of a macroscopic phospholipid membrane
at the surface of a rotating disc (40) has been extensively characterized for immobilized enzymes (33, 41, 42). Its main advantage
over flow systems like that of a capillary flow reactor (43, 44) is the
uniformly accessibility of the surface (40).
Determination of the Kinetics of FX Activation Using the Rotating
Disc System--
Our study confirms the role of anionic phospholipids
in the binding of FVIIa to TF embedded in a phospholipid bilayer: the Kd of FVIIa for TF·PC (240 pM) is
13-fold higher than the Kd of FVIIa for TF·PSPC
(18 pM).
The kcat (35 s
1) and
Km(app) (110 nM) values for
TF·FVIIa-catalyzed FX activation at PSPC are in reasonable agreement with the kcat = 12 s
1 and
Km = 70 nM measured at TF-bearing PSPC
vesicles (23, 45). However, others have reported much higher values (46). A trivial explanation for this apparent discrepancy could be the
high vesicle concentration in the latter study. The estimated occupancy
of the TF·FVIIa by FX, as determined from Km values in PSPC and PC is 47% and less than 2%, respectively,
suggesting that some competition between substrate and inhibitor for
TF·FVIIa might be expected at PSPC but not at PC.
Inhibition Kinetics of TF·FVIIa-catalyzed FX Activation as
Studied at a Rotating Disc Surface--
The similar kinetics of
TF·FVIIa inhibition that were observed for FXa·TFPIFL
and FXa·TFPI1-161 on a TF·PC surface, which does not
bind FXa (47) nor TFPIFL (48), are consistent with other
studies which indicated that a direct interaction of FXa·TFPI with
TF·FVIIa does not require the binding of FXa·TFPI to negatively
charged phospholipids (22, 43, 49). Kazama (50), however, concluded
from studies using TF lacking the trans-membrane and cytoplasmic
domains that binding of FXa to anionic phospholipids via its Gla domain
may be an absolute requirement for TFPI-mediated regulation of
full-length membrane-inserted TF.
Interestingly, the addition of PS (25%) to a neutral membrane brings
about a significant stimulation of the rate of inhibition by both
FXa·TFPIFL (k = 0.20 × 108 M
1·s
1) and
FXa·TFP1-161 (k = 0.94 × 108 M
1·s
1). We
note that the marked difference in fractional saturation of TF·FVIIa
on a PC membrane and that of TF·FVIIa on a PSPC membrane as
aforementioned could mask the stimulatory effect of PS. When FX and
FXa·TFPI compete for TF·FVIIa at PSPC, then it can be calculated according to the relation ktrue = kobs (1 + S/Km) that the true
rate constants of inhibition (FXa·TFPI1-161: 1.79 × 108 M
1 s
1,
FXa·TFPIFL: 0.38 × 108
M
1 s
1) are about 2-fold higher
then the observed rate constants (Table I). Because for TF·PC the
Km is much larger than the substrate concentration
[FX], competition is in this case negligible. As a result, the
differences in rate constants of inhibition at a membrane with PSPC and
pure PC become even more pronounced.
The stimulatory effect of PS on the inhibition of both
FXa·TFPI1-161 and FXa·TFPIFL might be
related to the FXa-mediated binding of the complexes to the
phospholipid membrane (24). Several mechanisms have been proposed to
explain the membrane-mediated acceleration of reactions of the blood
coagulation system. Next to a proper juxtaposition of the FXa·TFPI
complexes toward the active site of the FVIIa, anionic planar
phospholipid membranes may also allow lateral diffusion of the
substrate toward the membrane associated enzymatic complex as shown in
experiments on prothrombin activation (33, 34, 38). As a result, a much
lower solution phase substrate concentration is needed to saturate half
of the immobilized enzyme. If this mechanism would be operational for the inhibition of TF embedded in the PSPC membrane, one would predict
the highest rate constant of inhibition for the inhibitory complex with
the highest affinity for the membrane. Our experiments, however, show
the opposite; the presence of PS stimulated
FXa·TFPI1-161 9-fold compared with the only 3-fold
stimulation of FXa·TFPIFL. Apparently the high affinity
binding of FXa·TFPIFL with PSPC membranes is accompanied
by a lower inhibitory activity. These data thus suggest that solution
phase and membrane-bound FXa·TFPIFL contribute to the
overall inhibition reaction but to a different extent. Therefore, the
description of the inhibition reaction by a bimolecular association
reaction (Equation 3), although it adequately describes the experiment
of Figs. 3 and 4, presents a gross simplification. Indeed, the
experiments in Figs. 5 and 6 demonstrate that inhibition of TF·FVIIa
at PSPC by preadsorbed FXa·TFPIFL is in fact a multistep process. After a rapid inactivation of ± 75% of the TF·FVIIa
activity, as suggested by the reduced initial rate of FXa generation
after the addition of FVIIa and FX, a much slower elimination of the remaining activity is observed. This rapid first phase suggests that
the membrane-bound pool of FXa·TFPIFL may, also in the
absence of FVIIa, associate with TF (51) and that this ternary complex upon addition of FVIIa and FX rapidly converts to the quaternary complex. Alternatively, FXa·TFPIFL binding to TF could
interfere with the interaction of TF with FVIIa. However, the same
study on TF·PC showed no persistent inhibitory activity. This
indicates that the high affinity binding of FXa·TFPIFL to
TF·PSPC membranes is the result of a protein (FXa·TFPI)-lipid
interaction rather than a protein (FXa·TFPI)-protein (TF)
interaction. The decreasing extent of the initial inhibition with
increasing flushing time as shown in Table II, thus probably reflects
the decrease of the membrane-bound pool of
FXa·TFPIFL.
Taken together, our data indicate efficient inhibition both by fluid
phase FXa·TFPIFL and by phospholipid-bound complex. The complex between full-length TFPI and FXa is so tightly bound to the
catalytic TF·PSPC surface that it represents a highly effective pool
of inhibitory activity that remains available for hours after exposure
of the membrane to FXa·TFPIFL complexes. This property may be of physiological importance in allowing an on-site regulation of
the TF·FVIIa activity. That is, this phospholipid-bound pool of
inhibitor complex, which is immediately available, may represent an
effective control of newly formed catalytic units when newly synthesized TF arrives at the plasma membrane of TF producing cells.
 |
FOOTNOTES |
*
This work was supported by Grant 902-26-154 from the Dutch
Organization for Scientific Research.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Biochemistry, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Tel.: 31-43-3881674; Fax: 31-43-3884159; E-mail: t.lindhout@bioch.unimaas.nl.
 |
ABBREVIATIONS |
The abbreviations used are:
TF, tissue factor;
FVIIa, factor VIIa;
FIX, factor IX;
FX, factor X;
FXa, factor Xa;
PC, phosphatidylcholine;
PSPC, phosphatidylcholine-phosphatidylserine;
PS, phosphatidylserine;
TFPI, tissue factor pathway inhibitor;
BSA, bovine
serum albumin;
PETP, polyethylene terephthalate;
TBSA-CaCl2, Tris-BSA-CaCl2;
TBSA-EDTA, Tris-BSA-EDTA.
 |
REFERENCES |
| 1.
|
Nemerson, Y.
(1988)
Blood
71,
1-8[Free Full Text]
|
| 2.
|
Rapaport, S. I.,
and Rao, L. V.
(1995)
Thromb. Haemost.
74,
7-17[Medline]
[Order article via Infotrieve]
|
| 3.
|
Davie, E. W.,
Fujikawa, K.,
and Kisiel, W.
(1991)
Biochemistry
30,
10363-10370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Drake, T. A.,
Morrissey, J. H.,
and Edgington, T. S.
(1989)
Am. J. Pathol.
134,
1087-1097[Abstract]
|
| 5.
|
Fleck, R. A.,
Rao, L. V.,
Rapaport, S. I.,
and Varki, N.
(1990)
Thromb. Res.
59,
421-437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Broze, G. J.,
Girard, T. J.,
and Novotny, W. F.
(1990)
Biochemistry
29,
7539-7546[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Rapaport, S. I.
(1991)
Thromb. Haemost.
66,
6-15[Medline]
[Order article via Infotrieve]
|
| 8.
|
Wun, T. C.,
Kretzmer, K. K.,
Girard, T. J.,
Miletich, J. P.,
and Broze, G. J.
(1988)
J. Biol. Chem.
263,
6001-6004[Abstract/Free Full Text]
|
| 9.
|
Girard, T. J.,
Warren, L. A.,
Novotny, W. F.,
Likert, K. M.,
Brown, S. G.,
Miletich, J. P.,
and Broze, G. J., Jr.
(1989)
Nature
338,
518-520[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Petersen, L. C.,
Björn, S. E.,
Olsen, O. H.,
Nordfang, O.,
Norris, F.,
and Norris, K.
(1996)
Eur. J. Biochem.
235,
310-316[Medline]
[Order article via Infotrieve]
|
| 11.
|
Valentin, S.,
Nordfang, O.,
Bregengard, C.,
and Wildgoose, P.
(1993)
Blood Coag. Fibrinol.
4,
713-720[Medline]
[Order article via Infotrieve]
|
| 12.
|
Enjyoji, K.,
Miyata, T.,
Kamikubo, Y.,
and Kato, H.
(1995)
Biochemistry
34,
5725-5735[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Nordfang, O.,
Björn, S. E.,
Valentin, S.,
Nielsen, L. S.,
Wildgoose, P.,
Beck, T. C.,
and Hedner, U.
(1991)
Biochemistry
30,
10371-10376[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Wesselschmidt, R.,
Likert, K.,
Girard, T.,
Wun, T. C.,
and Broze, G. J.
(1992)
Blood
79,
2004-2010[Abstract/Free Full Text]
|
| 15.
|
Hamamoto, T.,
Yamamoto, M.,
Nordfang, O.,
Petersen, J. G.,
Foster, D. C.,
and Kisiel, W.
(1993)
J. Biol. Chem.
268,
8704-8710[Abstract/Free Full Text]
|
| 16.
|
Huang, Z. F.,
Wun, T. C.,
and Broze, G. J., Jr.
(1993)
J. Biol. Chem.
268,
26950-26955[Abstract/Free Full Text]
|
| 17.
|
Jesty, J.,
Wun, T. C.,
and Lorenz, A.
(1994)
Biochemistry
33,
12686-12694[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Lindhout, T.,
Willems, G. M.,
Blezer, R.,
and Hemker, H. C.
(1994)
Biochem. J.
297,
131-136
|
| 19.
|
Salemink, I.,
Franssen, J.,
Willems, G. M.,
Hemker, H. C.,
Li, A.,
Wun, T. C.,
and Lindhout, T.
(1998)
Thromb. Haemost.
80,
273-280[Medline]
[Order article via Infotrieve]
|
| 20.
|
Broze, G. J.,
Warren, L. A.,
Novotny, W. F.,
Higuchi, D. A.,
Girard, J. J.,
and Miletich, J. P.
(1988)
Blood
71,
335-343[Abstract/Free Full Text]
|
| 21.
|
Callander, N. S.,
Rao, L. V.,
Nordfang, O.,
Sandset, P. M.,
Warn-Cramer, B.,
and Rapaport, S. I.
(1992)
J. Biol. Chem.
267,
876-882[Abstract/Free Full Text]
|
| 22.
|
Baugh, R. J.,
Broze, G. J., Jr.,
and Krishnaswamy, S.
(1998)
J. Biol. Chem.
273,
4378-4386[Abstract/Free Full Text]
|
| 23.
|
Lindhout, T.,
Franssen, J.,
and Willems, G. M.
(1995)
Thromb. Haemost.
74,
910-915[Medline]
[Order article via Infotrieve]
|
| 24.
|
Willems, G. M.,
Janssen, M.,
Salemink, I.,
Wun, T. C.,
and Lindhout, T.
(1998)
Biochemistry
37,
3321-3328[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Nesheim, M. E.,
Tracy, R. P.,
and Mann, K. G.
(1984)
J. Biol. Chem.
259,
1447-1453[Abstract/Free Full Text]
|
| 26.
|
van Rijn, J. L.,
Govers-Riemslag, J. W.,
Zwaal, R. F.,
and Rosing, J.
(1984)
Biochemistry
23,
4557-4564[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Mertens, K.,
and Bertina, R. M.
(1980)
Biochem. J.
185,
647-658[Medline]
[Order article via Infotrieve]
|
| 28.
|
Lindhout, M. J.,
Kop-Klaassen, B. H.,
and Hemker, H. C.
(1978)
Biochim. Biophys. Acta
533,
327-341[Medline]
[Order article via Infotrieve]
|
| 29.
|
Smith, R. L.
(1973)
J. Biol. Chem.
248,
2418-2423[Abstract/Free Full Text]
|
| 30.
|
Diaz-Collier, J. A.,
Palmier, M. O.,
Kretzmer, K. K.,
Bishop, B. F.,
Combs, R. G.,
Obukowicz, M. G.,
Frazier, R. B.,
Bild, G. S.,
Joy, W. D.,
Hill, S. R.,
Duffin, K. L.,
Gustafson, M. E.,
Junger, K. D.,
Grabner, R. W.,
Galluppi, G. R.,
and Wun, T. C.
(1994)
Thromb. Haemost.
71,
339-346[Medline]
[Order article via Infotrieve]
|
| 31.
|
Petersen, J. G.,
Meyn, G.,
Rasmussen, J. S.,
Petersen, J.,
Björn, S. E.,
Jonassen, I.,
Christiansen, L.,
and Nordfang, O.
(1993)
J. Biol. Chem.
268,
13344-13351[Abstract/Free Full Text]
|
| 32.
|
Bach, R.,
Gentry, R.,
and Nemerson, Y.
(1986)
Biochemistry
25,
4007-4020[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Willems, G. M.,
Giesen, P. L.,
and Hermens, W. T.
(1993)
Blood
82,
497-504[Abstract/Free Full Text]
|
| 34.
|
Billy, D.,
Speijer, H.,
Willems, G. M.,
Hemker, H. C.,
and Lindhout, T.
(1995)
J. Biol. Chem.
270,
1029-1034[Abstract/Free Full Text]
|
| 35.
|
Andree, H. A.,
Contino, P. B.,
Repke, D.,
Gentry, R.,
and Nemerson, Y.
(1994)
Biochemistry
33,
4368-4374[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Neuenschwander, P. F.,
and Morrissey, J. H.
(1994)
J. Biol. Chem.
269,
8007-8013[Abstract/Free Full Text]
|
| 37.
|
Waxman, E.,
Ross, J. B.,
Laue, T. M.,
Guha, A.,
Thiruvikraman, S. V.,
Lin, T. C.,
Konigsberg, W. H.,
and Nemerson, Y.
(1992)
Biochemistry
31,
3998-4003[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Giesen, P. L.,
Willems, G. M.,
Hemker, H. C.,
and Hermens, W. T.
(1991)
J. Biol. Chem.
266,
18720-18725[Abstract/Free Full Text]
|
| 39.
|
Rao, L. V.,
Robinson, T.,
and Hoang, A. D.
(1992)
Thromb. Haemost.
67,
654-659[Medline]
[Order article via Infotrieve]
|
| 40.
|
Levich, V. G.
(1962)
Physicochemical Hydrodynamics
, Prentice-Hall, Englewood Cliffs, NJ
|
| 41.
|
Shu, F. R.,
and Wilson, G. S.
(1976)
Anal. Chem.
48,
1679-1686[Medline]
[Order article via Infotrieve]
|
| 42.
|
Castner, J. F.,
and Wingard, L. B.
(1984)
Biochemistry
23,
2203-2210[CrossRef][Medline]
[Order article via Infotrieve]
|
|